{
    "clinical_study": {
        "@rank": "82212", 
        "arm_group": [
            {
                "arm_group_label": "Liraglutide", 
                "arm_group_type": "Experimental", 
                "description": "1.8 mg liraglutide, subcutaneous, once-daily for five years"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, subcutaneous, once-daily for one year"
            }
        ], 
        "brief_summary": {
            "textblock": "It is well-known  that women with previous gestational diabetes mellitus are in risk of\n      developing type 2 diabetes later in life; approximately half of the women develop overt type\n      2 diabetes within the first 10 years after pregnancy. Knowing this, we want to examine the\n      effect of the type 2 diabetes medicine, liraglutide (Victoza), in women with previous\n      gestational diabetes with the aim of reducing the risk of developing type 2 diabetes."
        }, 
        "brief_title": "The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes", 
        "condition": "Gestational Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Diabetes, Gestational"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  informed oral and written consent\n\n          -  Previous diagnosis of GDM according to current Danish guidelines (mainly PG\n             concentrationa t 120 min after 75 g OGTT \u2265 9.0 mM) during pregnancy within the last 5\n             years\n\n          -  Age >18 years\n\n          -  25 kg/m2 < BMI < 45 kg/m2\n\n          -  NGT, IFG and or IGT\n\n          -  Safe contraception and negative pregnancy test\n\n        Exclusion Criteria:\n\n          -  Patients with diabetes\n\n          -  HbA1c  \u22656.5%\n\n          -  Patients with previous pancreatitis or previous neoplasia\n\n          -  Pregnant or breast feeding women\n\n          -  Anaemia (haemoglobin <7 mM)\n\n          -  Women planning to become pregnant within the next 5 years\n\n          -  Women using other contraception than intrauterine device (IUD) or oral\n             contraceptives. Women who do not use safe contraception will be offered application\n             of an IUD.\n\n          -  Women treated with statins, corticosteroids or other hormone therapy (except\n             estrogens and gestagens)\n\n          -  Ongoing abuse of alcohol or narcotics\n\n          -  Impaired hepatic function (liver transaminases >3 times upper normal limit)\n\n          -  Impaired renal function (se-creatinine >120 \u03bcM and/or albuminuria)\n\n          -  Uncontrolled hypertension (systolic blood pressure >180 mmHg, diastolic blood\n             pressure >100 mmHg)\n\n          -  Any condition that the investigator feels would interfere with trial participation\n\n          -  Receiving any investigational drug within the last 3 months"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795248", 
            "org_study_id": "GDM-TREAT", 
            "secondary_id": "2012-001371-37"
        }, 
        "intervention": [
            {
                "arm_group_label": "Liraglutide", 
                "description": "1.8 mg liraglutide", 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Victoza", 
                    "NN2211"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Liraglutide without the GLP-1 analogue", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Glucagon-Like Peptide 1"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "gestational diabetes mellitus", 
            "incretin", 
            "glucose homeostasis", 
            "GLP-1", 
            "type 2 diabetes mellitus", 
            "liraglutide", 
            "Victoza"
        ], 
        "lastchanged_date": "February 18, 2013", 
        "link": {
            "description": "Main website for the University Hospital Gentofte", 
            "url": "http://gentoftehospital.dk"
        }, 
        "location": {
            "contact": {
                "email": "Signe.Foghsgaard@regionh.dk", 
                "last_name": "Signe Foghsgaard, MD", 
                "phone": "+4539772058"
            }, 
            "contact_backup": {
                "email": "Louise.Vedtofte@regionh.dk", 
                "last_name": "Louise Vedtofte, M.Sc., PhD", 
                "phone": "+4539772688"
            }, 
            "facility": {
                "address": {
                    "city": "Hellerup", 
                    "country": "Denmark", 
                    "zip": "2900"
                }, 
                "name": "Diabetology Research Unit"
            }, 
            "investigator": [
                {
                    "last_name": "Signe Foghsgaard, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Louise Vedtofte, M.Sc., PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Filip K Knop, MD, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Gestational Diabetes Mellitus", 
        "other_outcome": [
            {
                "description": "Changes in glycated hemoglobin (HbA1c). From normoglycaemic to prediabetic or type 2 diabetic and from prediabetic to type 2 diabetic", 
                "measure": "Changes in glycated hemoglobin", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 52 wks and 260 wks"
            }, 
            {
                "description": "Changes in body mass index (BMI)(kg/m2), absolute body weight (kg), and waist:hip ratio", 
                "measure": "Changes in anthropometric measurements", 
                "safety_issue": "No", 
                "time_frame": "from baseline to 52 and 260 wks"
            }, 
            {
                "description": "changes in area under the curve during OGTT and isoglycemic intravenous glucose infusion (IIGI), the homeostatic model assessment (HOMA) and pro-insulin ratio", 
                "measure": "Changes in beta cell secretory responses", 
                "safety_issue": "No", 
                "time_frame": "from baseline to 52, 53, 260, and 261 wks"
            }, 
            {
                "description": "assessed by HOMA-IR and Matsuda insulin sensitivty index", 
                "measure": "Changes in insulin sensitivity", 
                "safety_issue": "No", 
                "time_frame": "from baseline to 52, 53, 260, and 261 wks"
            }, 
            {
                "description": "measured as fasting plasma concentrations and plasma responses of GLP-1, GLP2, and GIP and plasma glucagon during OGTT", 
                "measure": "Changes in incretin hormone secretion", 
                "safety_issue": "No", 
                "time_frame": "baseline to 52, 53, 260, and 261 wks"
            }, 
            {
                "description": "insulin and c-peptide responses after OGTT vs. IIGI", 
                "measure": "Changes in incretin effect", 
                "safety_issue": "No", 
                "time_frame": "baseline to 52, 53, 260, and 261 wks"
            }, 
            {
                "measure": "Changes in cardio-metabolic risk measures", 
                "safety_issue": "Yes", 
                "time_frame": "baseline to 52 and 260 wks"
            }, 
            {
                "measure": "Changes in subjective appetite", 
                "safety_issue": "No", 
                "time_frame": "baseline to 52, 53, 260, and 261 wks"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "baseline to 52 and 260 wks"
            }
        ], 
        "overall_contact": {
            "email": "Signe.Foghsgaard@regionh.dk", 
            "last_name": "Signe Foghsgaard, MD", 
            "phone": "+4539772058"
        }, 
        "overall_contact_backup": {
            "email": "Louise.Vedtofte@regionh.dk", 
            "last_name": "Louise Vedtofte, M.Sc., PhD", 
            "phone": "+4539772688"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Gentofte", 
            "last_name": "Tina Vilsb\u00f8ll, MD, DMSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Danish Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Changes in glucose is measured by area under the curve for the plasma glucose excursion following a 4-hour 75 g oral glucose tolerance test (OGTT)", 
            "measure": "Change in glucose tolerance", 
            "safety_issue": "No", 
            "time_frame": "from baseline to 52 wks, 53 wks, 260 wks, and 261 wks"
        }, 
        "reference": [
            {
                "PMID": "10842653", 
                "citation": "Porte D Jr. Mechanisms for hyperglycemia in the metabolic syndrome. The key role of beta-cell dysfunction. Ann N Y Acad Sci. 1999 Nov 18;892:73-83. Review."
            }, 
            {
                "PMID": "14968296", 
                "citation": "Vilsb\u00f8ll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia. 2004 Mar;47(3):357-66. Epub 2004 Feb 13. Review."
            }, 
            {
                "PMID": "16009062", 
                "citation": "Vilsb\u00f8ll T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus. Dan Med Bull. 2004 Nov;51(4):364-70."
            }, 
            {
                "PMID": "17928588", 
                "citation": "Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-39. Review."
            }, 
            {
                "PMID": "9742976", 
                "citation": "[No authors listed] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999 Aug 14;354(9178):602."
            }, 
            {
                "PMID": "8623813", 
                "citation": "Damm P, Vestergaard H, K\u00fchl C, Pedersen O. Impaired insulin-stimulated nonoxidative glucose metabolism in glucose-tolerant women with previous gestational diabetes. Am J Obstet Gynecol. 1996 Feb;174(2):722-9."
            }, 
            {
                "PMID": "14634573", 
                "citation": "Jensen DM, M\u00f8lsted-Pedersen L, Beck-Nielsen H, Westergaard JG, Ovesen P, Damm P. Screening for gestational diabetes mellitus by a model based on risk indicators: a prospective study. Am J Obstet Gynecol. 2003 Nov;189(5):1383-8."
            }, 
            {
                "PMID": "9704245", 
                "citation": "Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. Diabetes Care. 1998 Aug;21 Suppl 2:B161-7."
            }, 
            {
                "PMID": "15111544", 
                "citation": "Lauenborg J, Hansen T, Jensen DM, Vestergaard H, M\u00f8lsted-Pedersen L, Hornnes P, Locht H, Pedersen O, Damm P. Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population. Diabetes Care. 2004 May;27(5):1194-9."
            }, 
            {
                "PMID": "20682697", 
                "citation": "Xiang AH, Kjos SL, Takayanagi M, Trigo E, Buchanan TA. Detailed physiological characterization of the development of type 2 diabetes in Hispanic women with prior gestational diabetes mellitus. Diabetes. 2010 Oct;59(10):2625-30. doi: 10.2337/db10-0521. Epub 2010 Aug 3."
            }, 
            {
                "PMID": "12027921", 
                "citation": "Hanna FW, Peters JR. Screening for gestational diabetes; past, present and future. Diabet Med. 2002 May;19(5):351-8. Review."
            }, 
            {
                "PMID": "11776065", 
                "citation": "Bian X, Gao P, Xiong X, Xu H, Qian M, Liu S. Risk factors for development of diabetes mellitus in women with a history of gestational diabetes mellitus. Chin Med J (Engl). 2000 Aug;113(8):759-62."
            }, 
            {
                "PMID": "9715377", 
                "citation": "Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev. 1998 Aug;19(4):491-503. Review."
            }, 
            {
                "PMID": "21153530", 
                "citation": "Forbes S, Taylor-Robinson SD, Patel N, Allan P, Walker BR, Johnston DG. Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes. Diabetologia. 2011 Mar;54(3):641-7. doi: 10.1007/s00125-010-2009-0. Epub 2010 Dec 12."
            }, 
            {
                "PMID": "19853906", 
                "citation": "Astrup A, R\u00f6ssner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009 Nov 7;374(9701):1606-16. Epub 2009 Oct 23."
            }, 
            {
                "PMID": "21844879", 
                "citation": "Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, R\u00f6ssner S, Savolainen MJ, Van Gaal L; NN8022-1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012 Jun;36(6):843-54. doi: 10.1038/ijo.2011.158. Epub 2011 Aug 16. Erratum in: Int J Obes (Lond). 2012 Jun;36(6):890. Int J Obes (Lond). 2013 Feb;37(2):322."
            }, 
            {
                "PMID": "10702749", 
                "citation": "Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48."
            }, 
            {
                "PMID": "9449682", 
                "citation": "Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 Feb 1;101(3):515-20."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795248"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital, Gentofte, Copenhagen", 
            "investigator_full_name": "Tina Vilsboll", 
            "investigator_title": "Dr. Tina Vilsb\u00f8ll, DMSc", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Percentage of subjects in each treatment arm with normal glucose tolerance (NGT) at inclusion who develop impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) or type 2 diabetes; or with IFG or IGT who develop combined IFG/IGT; or with combined IFG/IGT who develop type 2 diabetes", 
            "measure": "Deterioration in glycaemic status", 
            "safety_issue": "No", 
            "time_frame": "from baseline to 52 wks, 53, wks, 260 wks, and 261 wks"
        }, 
        "source": "University Hospital, Gentofte, Copenhagen", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Novo Nordisk A/S", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Rigshospitalet, Denmark", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Tina Vilsboll", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}